Ventyx Biosciences is a technology company.
Ventyx Biosciences has raised $110.0M across 1 funding round.
Key people at Ventyx Biosciences.
Ventyx Biosciences has raised $110.0M in total across 1 funding round.
Ventyx Biosciences has raised $110.0M in total across 1 funding round.
Ventyx Biosciences's investors include Canaan Partners, Nextech Invest, venBio.
Key people at Ventyx Biosciences.
Ventyx Biosciences is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for autoimmune, inflammatory, and neurodegenerative diseases. It focuses on high-unmet-need conditions through expertise in medicinal chemistry, structural biology, and immunology, advancing candidates rapidly into clinical trials.[1][2][3] The company's lead programs include NLRP3 inhibitors like VTX2735 (Phase 2 for recurrent pericarditis) and VTX3232 (Phase 2 for neurodegenerative and cardiometabolic diseases), alongside inflammatory bowel disease assets such as tamuzimod (S1P1R modulator) and VTX958 (TYK2 inhibitor), both completing Phase 2 trials.[1][2] Ventyx serves patients with inflammatory and autoimmune disorders, addressing limitations of existing therapies by targeting specific pathways like TYK2 without broader JAK inhibition toxicities.[1][2]
Ventyx Biosciences was founded in 2019 by Raju Mohan, PhD, a serial entrepreneur in immunology-focused pharmaceuticals, based in California.[1][3] Mohan previously founded Akarna Therapeutics, acquired by Allergan for up to $1.2 billion, and other ventures like Oppilan Pharma, Zomagen Biosciences, and Vimalan Biosciences.[1] The company emerged from Mohan's vision to leverage advanced drug discovery for differentiated small molecules in immunology and inflammation. Key leadership includes John (likely John McKew, VP of Drug Discovery with 25+ years advancing 30+ molecules to clinic from roles at Ferring and Exelixis), strengthening early clinical progression.[1]
Ventyx rides the wave of precision immunology therapies, targeting inflammasome pathways like NLRP3 and specific kinases (TYK2, S1P1R) amid rising demand for safer oral alternatives to biologics in autoimmune and neurodegenerative diseases.[1][2] Timing aligns with maturing insights into disease mechanisms—e.g., NLRP3's role in pericarditis and neurodegeneration—fueled by market forces like aging populations, post-pandemic inflammation focus, and biopharma shifts to small molecules for better patient access.[1] As a NASDAQ-listed biotech (VTYX), it influences the ecosystem by validating selective inhibitors, potentially accelerating similar pipeline advancements and attracting investment in inflammation-focused biotechs.[2]
Ventyx's Phase 2 readouts for VTX2735, VTX3232, and prior bowel disease assets position it for potential Phase 3 entry or partnerships by 2026-2027, with NLRP3 and TYK2 programs addressing multi-billion-dollar markets.[1][2] Trends like AI-driven drug design and combo therapies for neurodegeneration will shape its path, amplifying founder-led momentum. Its influence may grow through acquisitions or approvals, evolving from clinical-stage player to key innovator in oral immunology, much like Mohan's prior Akarna success.[1]
Ventyx Biosciences has raised $110.0M across 1 funding round. Most recently, it raised $110.0M Series A in March 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2021 | $110.0M Series A | Canaan Partners, Nextech Invest, venBio |
